Buy Ratings for RE, NOTE, NAK, CPRX - Uncovering Growth Prospects
- June 21st, 2023
- 328 views
Citigroup initiated coverage on Everest Re Group, Ltd. (NYSE: RE), a global provider of insurance and reinsurance products, with a Buy rating and set a price target of $406.
Considering the closing price of $352.74 on Tuesday, the assigned price target suggests a potential upside of $53.26 or 15.09% for $RE, based on the investment firm's assessment.
ROTH MKM initiated coverage on FiscalNote Holdings, Inc. (NYSE: NOTE), a technology company specializing in government relationship management solutions, with a Buy rating and a price target of $4.75.
With $NOTE closing at $3.42 on Tuesday, the projected price target indicates a potential upside of $1.33 or 38.88% according to ROTH MKM's analysis.
HC Wainwright & Co. maintained its Buy rating on Northern Dynasty Minerals Ltd. (NYSE American: NAK), a mineral exploration company focused on developing the Pebble Project in Alaska, and raised the price target from $0.80 to $0.90.
Despite closing at $0.22 on Tuesday, the adjusted price target implies a potential upside of $0.68 or 309.09% for $NAK, based on the investment banking firm's evaluation.
Truist Securities maintained its Buy rating on Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company specializing in rare neurological diseases, and raised the price target from $22 to $24.
With $CPRX closing at $12.62 on Tuesday, the revised price target suggests a potential upside of $11.38 or 90.23%, according to the financial services firm's view.
Please note that the potential upsides mentioned for these companies are based on the analysis and recommendations of brokerage firms, investment firms, or analysts, reflecting their outlook on the future performance of each company. Investors should conduct their own research and consider other factors before making any investment decisions.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025




Member Login